Clinical significance of cancer-related fatigue in multiple myeloma patients

Researchers analyzing a small cohort of 16 patients with newly diagnosed or relapsed/refractory multiple myeloma who were treated with proteasome inhibitors and immunomodulatory drugs found that the patients who experienced cancer-related fatigue (CRF) as an adverse event (54.9%) also had significantly shorter overall survival and progression-free survival than patients without CRF and that reactivation of HHV-6 and HHV-7 was not related to the CRF. They note that further studies in larger patient cohorts are warranted.

International Journal of Hematology